A Phase 3 interventional study of Abiraterone acetate and Placebo in Prostate Cancer, sponsored by Janssen Research & Development, LLC. Completed at 135 sites in 11 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 5th largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 8th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Men only
Deventer Ziekenhuis · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 67 · Phase 3 11 · Phase 4 4
First in 2005; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,088 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 56 across the 98 interventional studies. Of the 60 that completed or were terminated, 40 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 6th largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2009, is one of 15 in phase 3, and was the 13th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
8 of the studies testing Abiraterone Acetate in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
| NCT01786265M.D. Anderson Cancer CenterFinite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | 2027-02-01 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC).
This is a randomized (individuals will be assigned by chance to study treatments), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study in approximately 1,000 medically or surgically castrated male patients with metastatic CRPC who have shown tumor progression and are asymptomatic or mildly symptomatic. The study period will consist of screening, treatment, and follow-up phases. Patients will receive study treatment (abiraterone acetate or placebo) plus prednisone until radiographic progression of disease and/or unequivocal clinical progression. Efficacy evaluations will be performed throughout the treatment period and safety will be assessed until 30 days after the last dose of abiraterone acetate. throughout the study. Follow-up will continue for up to 60 months (5 years) or until the patient dies, is lost to follow-up, or withdraws informed consent. At the interim analysis of overall survival (OS; 43% of death events), the independent data monitoring committee (IDMC) reviewed the efficacy and safety data and concluded that all of the data pointed to a significant advantage for patients in one arm of the study compared with the other arm thereby unanimously recommending unblinding the study and allowing crossover from the placebo arm to active therapy. Patients currently receiving placebo will be offered crossover therapy to abiraterone acetate. Treatment for patients who were originally randomized to the abiraterone acetate treatment group will not change. Patients will be discontinued from long term follow-up at the time of the Clinical Cut-Off Date for Final Analysis (CCO-FA); however, patients still receiving treatment with abiraterone acetate at the CCO-FA will be offered to receive continued treatment for an additional period of up to 3 years or until disease progression or unacceptable toxicity. For these patients, safety assessment will be performed while continuing treatment, and for 30 days after the last dose of abiraterone acetate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo plus prednisone
Drug: Placebo · Drug: Prednisone
Abiraterone acetate plus prednisone
Drug: Abiraterone acetate · Drug: Prednisone
1000 mg per day (4 x 250-mg tablets) taken orally.
4 placebo tablets per day taken orally.
5 mg tablet orally twice daily.
Overall Survival
Overall survival is defined as the time from randomization to date of death from any cause.
Time frame: From randomization (Day 1) up to end of study (Month 60)
Radiographic Progression-free Survival (rPFS)
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.
Time frame: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
Time to Opiate Use for Prostate Cancer Pain
The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.
Time frame: From randomization (Day 1) up to first opiate use or end of study (Month 60)
Time to Initiation of Cytotoxic Chemotherapy
The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.
Time frame: From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)
Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point
The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.
Time frame: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
Time to Prostate-specific Antigen (PSA) Progression
The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.
Time frame: From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)
Number of Participants With Treatment Emergent Adverse Events
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.
Time frame: From first dose of study drug up to 30 days after the last dose of study drug
Mean Plasma Concentrations of Abiraterone
Time frame: Up to Cycle 5, Day 1
Maximum Plasma Concentrations of Abiraterone
Time frame: Up to Cycle 5, Day 1
Area Under the Plasma Concentration-time Curve From Time 0 to Time the Last Quantifiable Concentration of Abiraterone (AUC[0-infinity])
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
Time frame: Up to Cycle 5, Day 1
Elimination Half-Life (t1/2)
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
Time frame: Up to Cycle 5, Day 1
| Milestone | Abiraterone Acetate + Prednisone (AAP) | Placebo | Placebo to AA |
|---|---|---|---|
| Started | 546 | 542 | 0 |
| Treated | 542 | 540 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 546 | 542 | 0 |
| Withdrew: Ongoing | 42 | 0 | 0 |
| Withdrew: Adverse event | 50 | 33 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Cross-over to aa (under amendment 3) | 0 | 51 | 0 |
| Withdrew: Withdrawal by subject | 41 | 56 | 0 |
| Withdrew: Progressive disease | 366 | 370 | 0 |
| Withdrew: Other | 42 | 30 | 0 |
| Withdrew: Randomized, not treated | 4 | 2 | 0 |
| Milestone | Abiraterone Acetate + Prednisone (AAP) | Placebo | Placebo to AA |
|---|---|---|---|
| Started | 0 | 0 | 93 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 93 |
| Withdrew: Started other prostate cancer treatment | 0 | 0 | 8 |
| Withdrew: Ongoing | 0 | 0 | 35 |
| Withdrew: Adverse event | 0 | 0 | 9 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
| Withdrew: Progressive disease | 0 | 0 | 20 |
| Withdrew: Other | 0 | 0 | 19 |
Overall survival is defined as the time from randomization to date of death from any cause.
| Months | Abiraterone Acetate + Prednisone (AAP) | Placebo |
|---|---|---|
| Overall Survival | 34.66 (32.72 to 36.80) | 30.29 (28.65 to 33.28) |
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (\>=) 2 new lesions compared to baseline was observed in less than (\<) 12 weeks from randomization and was confirmed by a second bone scan taken \>=6 weeks later showing \>=2 additional new lesions (a total of \>=4 new lesions compared to baseline), b) the first bone scan with \>=2 new lesions compared to baseline was observed in \>=12 weeks from randomization and the new lesions were verified on the next bone scan \>=6 weeks later (a total of \>=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.
| Months | Abiraterone Acetate + Prednisone (AAP) | Placebo |
|---|---|---|
| Radiographic Progression-free Survival (rPFS) | NA (11.66 to NA) | 8.28 (8.12 to 8.54) |
The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.
| Months | Abiraterone Acetate + Prednisone (AAP) | Placebo |
|---|---|---|
| Time to Opiate Use for Prostate Cancer Pain | 33.38 (30.23 to 39.75) | 23.39 (20.27 to 27.53) |
The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.
| Months | Abiraterone Acetate + Prednisone (AAP) | Placebo |
|---|---|---|
| Time to Initiation of Cytotoxic Chemotherapy | 25.17 (23.26 to NA) | 16.82 (14.55 to 19.38) |
The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.
| Months | Abiraterone Acetate + Prednisone (AAP) | Placebo |
|---|---|---|
| Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point | 12.29 (11.33 to 14.29) | 10.87 (9.49 to 11.76) |
The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.
| Months | Abiraterone Acetate + Prednisone (AAP) | Placebo |
|---|---|---|
| Time to Prostate-specific Antigen (PSA) Progression | 11.07 (8.51 to 11.24) | 5.55 (5.39 to 5.59) |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.
| Participants | Abiraterone Acetate + Prednisone (AAP) | Placebo | Placebo to Abiraterone Acetate |
|---|---|---|---|
| With Treatment-Emergent Adverse Events | 541 | 524 | 93 |
| With Treatment-Emergent Serious Adverse Events | 208 | 148 | 39 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
No measurements were reported for this outcome.
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
No measurements were reported for this outcome.
Collected over From first dose of study drug up to 30 days after the last dose of study drug (Approximately 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abiraterone Acetate + Prednisone (AAP) | — | 215/542 (39.7%) | 530/542 (97.8%) |
| Placebo | — | 156/540 (28.9%) | 505/540 (93.5%) |
| Placebo to AA | — | 40/93 (43%) | 86/93 (92.5%) |
| Event | Abiraterone Acetate + Prednisone (AAP) | Placebo | Placebo to AA |
|---|---|---|---|
| Disease ProgressionGeneral disorders | 8/542 | 4/540 | 6/93 |
| Urinary Tract InfectionInfections and infestations | 14/542 | 4/540 | 5/93 |
| HaematuriaRenal and urinary disorders | 11/542 | 5/540 | 3/93 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 10/542 | 12/540 | 1/93 |
| FatigueGeneral disorders | 2/542 | 0/540 | 2/93 |
| CellulitisInfections and infestations | 2/542 | 3/540 | 2/93 |
| Myocardial InfarctionCardiac disorders | 4/542 | 5/540 | 2/93 |
| Subdural HaematomaInjury, poisoning and procedural complications | 0/542 | 2/540 | 2/93 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 1/542 | 1/540 | 2/93 |
| Calculus BladderRenal and urinary disorders | 0/542 | 0/540 | 2/93 |
| Event | Abiraterone Acetate + Prednisone (AAP) | Placebo | Placebo to AA |
|---|---|---|---|
| FatigueGeneral disorders | 243/542 | 200/540 | 27/93 |
| Back PainMusculoskeletal and connective tissue disorders | 199/542 | 180/540 | 26/93 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 172/542 | 131/540 | 19/93 |
| Oedema PeripheralGeneral disorders | 148/542 | 119/540 | 22/93 |
| ConstipationGastrointestinal disorders | 144/542 | 112/540 | 15/93 |
| NauseaGastrointestinal disorders | 144/542 | 127/540 | 15/93 |
| Bone PainMusculoskeletal and connective tissue disorders | 144/542 | 112/540 | 14/93 |
| DiarrhoeaGastrointestinal disorders | 135/542 | 98/540 | 13/93 |
| HypertensionVascular disorders | 129/542 | 73/540 | 6/93 |
| Hot FlushVascular disorders | 124/542 | 100/540 | 6/93 |
| Age, Continuous(years) | Abiraterone Acetate + Prednisone (AAP) | Placebo | Total |
|---|---|---|---|
| Mean | 70.5 ± 8.8 | 70.1 ± 8.72 | 70.3 ± 8.76 |
| Sex: Female, Male(Participants) | Abiraterone Acetate + Prednisone (AAP) | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 546 | 542 | 1088 |
| Region of Enrollment(Participants) | Abiraterone Acetate + Prednisone (AAP) | Placebo | Total |
|---|---|---|---|
| Australia | 60 | 72 | 132 |
| Belgium | 25 | 17 | 42 |
| Canada | 63 | 37 | 100 |
| France | 24 | 29 | 53 |
| Germany | 46 | 32 | 78 |
| Greece | 7 | 7 | 14 |
| Italy | 1 | 6 | 7 |
| Netherlands | 15 | 15 | 30 |
| Spain | 25 | 20 | 45 |
| Sweden | 4 | 13 | 17 |
| United Kingdom | 42 | 56 | 98 |
| United States | 234 | 238 | 472 |
Showing the first 100 of 135 sites across 11 countries. Choose a country and city above to see the rest.
Ran from Apr 2009 to primary completion in Mar 2014, 59 months.
Results were first posted in Apr 2015, 1 year after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 59 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abiraterone Acetate
Janssen Research & Development, LLC →